INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM

23.09.25 16:00 Uhr

Werte in diesem Artikel
Aktien

58,35 EUR 1,05 EUR 1,83%

NEW YORK, Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

The investigation concerns whether DexCom and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 18, 2025, Hunterbrook Media ("Hunterbrook") published a short report entitled "Dexcom's Fatal Flaws".  The Hunterbrook report alleged, among other things, that Dexcom "made an unauthorized design change to a key component of the G7", the Company's continuous glucose monitoring system for diabetes management, and that "G7 users have been hospitalized and died" following inaccurate glucose readings from G7 devices. 

On this news, Dexcom's stock price fell $8.99 per share, or 11.76%, over the following two trading sessions, to close at $67.45 per share on September 19, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-dexcom-inc---dxcm-302564094.html

SOURCE Pomerantz LLP

In eigener Sache

Übrigens: DexCom und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf DexCom

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf DexCom

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu DexCom Inc.

Wer­bung

Analysen zu DexCom Inc.

DatumRatingAnalyst
02.08.2018DexCom BuyCanaccord Adams
03.05.2018DexCom BuyCanaccord Adams
23.03.2018DexCom OutperformRobert W. Baird & Co. Incorporated
28.09.2017DexCom OutperformWedbush Morgan Securities Inc.
15.09.2017DexCom Equal WeightBarclays Capital
DatumRatingAnalyst
02.08.2018DexCom BuyCanaccord Adams
03.05.2018DexCom BuyCanaccord Adams
23.03.2018DexCom OutperformRobert W. Baird & Co. Incorporated
28.09.2017DexCom OutperformWedbush Morgan Securities Inc.
03.05.2017DexCom BuyCanaccord Adams
DatumRatingAnalyst
15.09.2017DexCom Equal WeightBarclays Capital
30.04.2015DexCom PerformOppenheimer & Co. Inc.
27.01.2015DexCom PerformOppenheimer & Co. Inc.
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DexCom Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen